Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

被引：0
|
作者：
Faidon-Marios Laskaratos
Martin Walker
Keval Naik
Emmanouil Maragkoudakis
Nikolaos Oikonomopoulos
Lee Grant
Tim Meyer
Martyn Caplin
Christos Toumpanakis
机构：
[1] Centre for Gastroenterology,Department of Infectious Disease Epidemiology
[2] Neuroendocrine Tumour Unit,Department of Radiology
[3] Centre for Gastroenterology,undefined
[4] Royal Free Hospital NHS Foundation Trust,undefined
[5] School of Public Health,undefined
[6] Faculty of Medicine,undefined
[7] Imperial College London,undefined
[8] Royal Free Hospital NHS Foundation Trust,undefined
[9] UCL Cancer Institute,undefined
[10] University College London,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
octreotide LAR; neuroendocrine tumours; antiproliferative activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1321 / 1327
页数：6
相关论文
共 50 条
  • [41] First-Line Therapy with Bevacizumab - Standard in advanced Ovarian Carcinoma
    Pohlmann, Birgit-Kristin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 382 - 383
  • [42] Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer
    Shiota, Masaki
    Blas, Leandro
    Kobayashi, Satoshi
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Shiga, Ken-ichiro
    Yokomizo, Akira
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) : 26 - 32
  • [43] Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412
    Goldman, B. H.
    Lara, P. N., Jr.
    Beer, T. M.
    Mack, P. C.
    Drabkin, H. A.
    Holland, W. S.
    Crawford, E.
    Ryan, C. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Prognostic Factors and Predictive Model in Patients With Advanced Biliary Tract Adenocarcinoma Receiving First-Line Palliative Chemotherapy
    Park, Inkeun
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Kim, Tae-Won
    Lee, Sung Sook
    Park, Do Hyun
    Lee, Sang Soo
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    CANCER, 2009, 115 (18) : 4148 - 4155
  • [45] Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor
    Lin, Li-Zhu
    Li, Peng
    Chen, Han-Rui
    Pang, Ling-Juan
    FUTURE ONCOLOGY, 2013, 9 (06) : 909 - 913
  • [46] Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
    Gallo, Marco
    Malandrino, Pasqualino
    Fanciulli, Giuseppe
    Rota, Francesca
    Faggiano, Antongiulio
    Colao, Annamaria
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1209 - 1224
  • [47] Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
    Marco Gallo
    Pasqualino Malandrino
    Giuseppe Fanciulli
    Francesca Rota
    Antongiulio Faggiano
    Annamaria Colao
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1209 - 1224
  • [48] Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours
    Lepage, Come
    Dahan, Laetitia
    Bouarioua, Nadia
    Toumpanakis, Christos
    Legoux, Jean-Louis
    Le Malicot, Karine
    Guimbaud, Rosine
    Smith, Denis
    Tougeron, David
    Lievre, Astrid
    Cadiot, Guillaume
    Di Fiore, Frederic
    Bouhier-Leporrier, Karine
    Hentic, Olivia
    Faroux, Roger
    Pavel, Marianne
    Borbath, Ivan
    Valle, Juan W.
    Rinke, Anja
    Scoazec, Jean-Yves
    Ducreux, Michel
    Walter, Thomas
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (05) : 568 - 571
  • [49] Updated Safety and Efficacy Results From RADIANT-2-a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus plus Octreotide LAR Vs Placebo plus Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)
    Ricci, S.
    Ruszniewski, P.
    Tomasetti, P.
    Jehl, V.
    Saletan, S.
    Yao, J. C.
    Pavel, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S461 - S461
  • [50] Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci, LC
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) : 2578 - 2578
12345